🔬 NeuroSense Therapeutics Ltd has entered into a collaboration with Lonza AG to advance theranostics in neurodegeneration.
🧪 The collaboration will focus on identifying exosome-based biomarkers for early diagnosis and treatment.
💡 NeuroSense’s lead candidate for ALS, Prime C, has shown promising results in Phase IIb studies.
🤝 The partnership will leverage Lonza’s expertise in extracellular vesicles to develop methods for measuring biomarkers. 🧠
🧪 The collaboration will focus on identifying exosome-based biomarkers for early diagnosis and treatment.
💡 NeuroSense’s lead candidate for ALS, Prime C, has shown promising results in Phase IIb studies.
🤝 The partnership will leverage Lonza’s expertise in extracellular vesicles to develop methods for measuring biomarkers. 🧠
📢 Breakthrough Collaboration: Lonza AG and NeuroSense Revolutionize Neurodegeneration Research
Introduction: Swiss company Lonza AG has entered into a research and development collaboration with NeuroSense Therapeutics Ltd to identify exosome-based biomarkers for neurodegenerative diseases.
Main points:
- NeuroSense Therapeutics has successfully reached the primary and secondary safety and efficacy endpoints in a Phase IIb study with its lead candidate for amyotrophic lateral sclerosis (ALS), called Prime C, which combines ciprofloxacin and celecoxib.
- The collaboration with Lonza AG aims to develop a method utilizing Neuron-Derived Exosomes (NDEs) to evaluate biological changes occurring in people with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
- NDEs are small extracellular vesicles that encapsulate various molecules and can pass the blood-brain barrier, providing a noninvasive depiction of the physiological status of neurons in the brain.
- Lonza AG will provide its expertise in extracellular vesicles, while NeuroSense Therapeutics will contribute its experience in utilizing biomarkers in neurodegenerative diseases.
- The collaboration aims to advance early diagnosis and treatment in the field of neurodegeneration.
Conclusion:
The collaboration between Lonza AG and NeuroSense Therapeutics Ltd aims to develop a method utilizing Neuron-Derived Exosomes (NDEs) to evaluate biological changes in neurodegenerative diseases. By identifying exosome-based biomarkers, the collaboration seeks to advance early diagnosis and treatment options for diseases such as Alzheimer’s, Parkinson’s, and ALS.
